Patents by Inventor Christopher L. Pelloni

Christopher L. Pelloni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cannabinoid formulations for inhalation
    Patent number: 10588870
    Abstract: A cannabinoid active agent containing formulation comprising the active agent, an HFA propellant, optionally a terpenoid, and optionally a co-solvent is disclosed. At least two cannabinoids, each of which is required to be present in amounts of at least 20% of the total cannabinoid content of formulation are required to be present. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 40° C.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: March 17, 2020
    Assignee: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Low-temperature inhalation administration of cannabinoid entities
    Patent number: 10537533
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: January 21, 2020
    Assignee: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Low-Temperature Inhalation Administration of Cannabinoid Entities
    Publication number: 20180360772
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Application
    Filed: July 19, 2018
    Publication date: December 20, 2018
    Applicant: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Cannabinoid Formulations For Inhalation
    Publication number: 20180344634
    Abstract: A cannabinoid active agent containing formulation comprising the active agent, an HFA propellant, optionally a terpenoid, and optionally a co-solvent is disclosed. At least two cannabinoids, each of which is required to be present in amounts of at least 20% of the total cannabinoid content of formulation are required to be present. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 40° C.
    Type: Application
    Filed: July 25, 2018
    Publication date: December 6, 2018
    Applicant: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Low-temperature inhalation administration of cannabinoid entities
    Patent number: 10064821
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: September 4, 2018
    Assignee: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Low-Temperature Inhalation Administration of Cannabinoid Entities
    Publication number: 20180000731
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Application
    Filed: June 27, 2017
    Publication date: January 4, 2018
    Applicant: EP Pharma, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Low-temperature inhalation administration of cannabinoid entities
    Patent number: 9717683
    Abstract: A cannabinoid material as active agent containing formulation comprising the active agent, an HFA propellant, and optionally a co-solvent is disclosed. Also disclosed is an inhalation method of administration of the formulation without the use of heat greater than 50° C.
    Type: Grant
    Filed: June 29, 2016
    Date of Patent: August 1, 2017
    Assignee: EP PHARMA, LLC
    Inventors: Charles Raymond Eck, Christopher L. Pelloni
  • Proton pump inhibitor formulation
    Publication number: 20020064555
    Abstract: Pharmaceutical capsule dosage forms of benzimidazole proton pump inhibitors are prepared by enclosing one or several enteric coated compressed cores in a capsule shell. The inventive formulations are stable and have higher bioavailability of the active ingredient relative to pellet and granule containing formulations.
    Type: Application
    Filed: September 25, 2001
    Publication date: May 30, 2002
    Inventors: Dan Cullen, Christopher L. Pelloni
  • Terazosin capsules
    Patent number: 6110493
    Abstract: A capsule dosage form containing solid form of terazosin in a solid carrier is disclosed. The capsule dosage form is stable under accelerated stability conditions and therapeutically equivalent to known liquid-filled terazosin capsules.
    Type: Grant
    Filed: May 18, 1999
    Date of Patent: August 29, 2000
    Assignee: Novartis Corporation
    Inventors: Jeffrey W. Guentensberger, Christopher L. Pelloni
  • Terazosin capsules
    Patent number: 5952003
    Abstract: A capsule dosage form containing solid form of terazosin in a solid carrier is disclosed. The capsule dosage form is stable under accelerated stability conditions and therapeutically equivalent to known liquid-filled terazosin capsules.
    Type: Grant
    Filed: August 1, 1996
    Date of Patent: September 14, 1999
    Assignee: Novartis Corporation
    Inventors: Jeffrey W. Guentensberger, Christopher L. Pelloni